Platform for Subcutaneous
Wearable Bolus Injection (WBI)

Platform for Subcutaneous
Wearable Bolus Injection (WBI)

Cost-effective

Cost-effective

Reliable

Reliable

Versatile

Versatile

Flexible

Flexible

Why

Subcuject Wearable Bolus Injection(WBI) enables longer delivery time for large, viscous doses

Convenient delivery of biologicals often requires an injection time over several minutes. The Subcuject WBI allows for convenient self-administration of large doses over a preset delivery period to avoid injection site leakage, local intolerability, injection pain etc.

Subcuject WBI enables reduced dosing frequency

The convenient self-administration of large doses with Subcuject WBI enables a change from delivery of many small doses to fewer larger doses.

Subcuject WBI enables cost saving in hospitals

Administration of pharmaceuticals via intra-veneous (IV) infusion in a hospital is costly. Patient self-administration of subcutaneous injections is expected to save from 30% to 70% of costs. In addition, the patient’s quality of life is improved with a self-administered wearable injector used in the home environment.

Close to 100 biologics (marketed or under development) are suited for delivery via Large Volume Wearable Injectors. These biologics are for treatment of chronic conditions, requiring frequent dosing, and are not currently available in suitable self-administration systems.

Roots Analysis Private Ltd 2017

Platform

The cost-effective Subcuject Platform provides a wide range of advantages:

  • Pre-filled and pre-loaded
  • Thin needle
  • Adaptable to customized and standard cartridges in glass or polymer
  • Dimensions smaller than state of the art
  • Simple activation and noiseless operation
  • Inserts needle at activation, and retracts needle automatically after completed injection
  • Injects drugs with high viscosities
  • Accommodates high dose volumes
  • Injection speed can be preset from fast to very slow
  • No electronics needed for operation
Wearable Bolus Injection

High viscosity requires a high drive force.

Complex and expensive device mechanisms with batteries and electronics are commonly used to achieve sufficient injection pressure at a slow speed.

The Subcuject WBI utilizes the newest forward osmosis technology to generate force. In simplified terms two chambers of liquid are separated by a semipermeable membrane. Adding a salt to one chamber draws in liquid from the other chamber. Hereby hydraulic/mechanical pressure for drug injection is generated. Simple and cost-effective.

Pending patents cover core and peripheral functionality.

Wearable Bolus Injection principle

The proprietary Subcuject device platform:
Flexible, versatile and cost-effective

Patients, therapies, drug substances and dose sizes are not equal across a product portfolio. This requires device customization. Our modular design enables straight forward configuration of the optimal combination of modules – across the product portfolio.

The Subcuject WBI Platform does not require electronics. Instead, it has the flexibility to accommodate any electronics as an add-on e.g. for connectivity or data collection.

Device platform subcuject

Collaboration

We welcome you to contact us for a dialogue on how the Subcuject WBI Platform can accommodate your need for patient-centric, cost-effective and proprietary wearable injection devices.

We focus on collaboration opportunities aimed at development and commercialization of the Subcuject WBI Platform.

Contact:

Claus Schmidt Møller
cms@subcuject.com

About

Subcuject develops an innovative and proprietary device platform for Wearable Bolus Injection.

Subcuject is organized as a virtual organization, applying external experts and specialist organizations.

Our management team and board has decades of experience and track record in medtech, pharma and drug delivery.

We are located near Copenhagen, and financed by the Danish venture funds Vaekstfonden and Capnova.

capnova & vækstfonden subcuject

Management

Jesper Roested member of the board

Jesper Roested

CEO
+45 2122 7772

Partner at VF Venture, investing in innovative medtech and technology Companies. M.Sc. Medical Physics and

...
Read More
Jesper Roested member of the board
Jesper Roested

CEO

Partner at VF Venture, investing in innovative medtech and technology Companies. M.Sc. Medical Physics and Electronics. Broad experience in the medical technology/medtech/ life science industries, former CEO at 3D, Danish Diagnostic Development A/S, nuclear medicine scanners. Multiple positions at Novo Nordisk A/S, primarily in business development on drugs and devices, as well as strategy consulting with McKinsey & Co.

Claus Schmidt Møller inventor, Founder and CTO

Claus Schmidt Møller

Inventor, Founder and CTO
+45 2773 6420

B. Sc. Mechanical Engineering. 20+ years of track record in innovation of drug delivery devices. Inventor of Novopen

...
Read More
Claus Schmidt Møller inventor, Founder and CTO
Claus Schmidt Møller

Inventor, Founder and CTO

B. Sc. Mechanical Engineering. 20+ years of track record in innovation of drug delivery devices. Inventor of Novopen 4 & 5 and co-inventor of Flexpen and Flextouch for Novo Nordisk. Several inventions of various medical devices made for or licensed to major Pharma and drug delivery companies. Mentioned as inventor or co-inventor on 60+ patent families.

Jesper Roested member of the board

Jesper Roested

CEO

Partner at VF Venture, investing in innovative medtech and technology Companies. M.Sc. Medical Physics and Electronics. Broad

...
Read More
Jesper Roested member of the board
Jesper Roested

CEO

Partner at VF Venture, investing in innovative medtech and technology Companies. M.Sc. Medical Physics and Electronics. Broad experience in the medical technology/medtech/ life science industries, former CEO at 3D, Danish Diagnostic Development A/S, nuclear medicine scanners. Multiple

Claus Schmidt Møller inventor, Founder and CTO

Claus Schmidt Møller

Inventor, Founder and CTO

B. Sc. Mechanical Engineering. 20+ years of track record in innovation of drug delivery devices. Inventor of Novopen 4 &

...
Read More
Claus Schmidt Møller inventor, Founder and CTO
Claus Schmidt Møller

Inventor, Founder and CTO

B. Sc. Mechanical Engineering. 20+ years of track record in innovation of drug delivery devices. Inventor of Novopen 4 & 5 and co-inventor of Flexpen and Flextouch for Novo Nordisk. Several inventions of various medical devices made for or licensed

Board of Directors

Lars Guldbæk Karlsen

Chairman of the Board

Senior Vice President, Product Supply Quality in Novo Nordisk A/S. M.Sc. And Ph.D. in chemical engineering. 30+ of

...
Read More
Lars Guldbæk Karlsen

Chairman of the Board

Senior Vice President, Product Supply Quality in Novo Nordisk A/S. M.Sc. And Ph.D. in chemical engineering. 30+ of pharma management experience from Novo Nordisk, hereof sixteen years in SVP positions. During nine years Chairman of the Board in Møller & Devicon A/S, special machine manufacturer to pharma industry.

Claus Demant member of the board

Claus Demant

Co-founder and Member of the Board

General Manager, Glyn Peter Machin A/S. E*MBA from SIMI, HD (A) from Copenhagen Business School. 25 years of

...
Read More
Claus Demant member of the board
Claus Demant

Co-founder and Member of the Board

General Manager, Glyn Peter Machin A/S. E*MBA from SIMI, HD (A) from Copenhagen Business School. 25 years of experience in leadership, strategy, business development, and international experience from IT, Electronics and MedTech industry. Regional Leadership positions in Creative Labs and SVP position in Daymen Acquisition S.A.

Paul Jansen

Member of the board

Former Global Head of Medical Device Development for Sanofi. Professional Engineer with more than twenty-five years of experience

...
Read More
Paul Jansen

Member of the board

Former Global Head of Medical Device Development for Sanofi. Professional Engineer with more than twenty-five years of experience in medical devices. Extensive experience in the design, development, manufacturing and lifecycle management of medical devices, including Lantus SoloStar. Active member of the International Standards Organisation and currently co-chair of TC84.

Lars Guldbæk Karlsen

Chairman of the Board

Senior Vice President, Product Supply Quality in Novo Nordisk A/S. M.Sc. And Ph.D. in chemical engineering. 30+ of pharma management

...
Read More
Lars Guldbæk Karlsen

Chairman of the Board

Senior Vice President, Product Supply Quality in Novo Nordisk A/S. M.Sc. And Ph.D. in chemical engineering. 30+ of pharma management experience from Novo Nordisk, hereof sixteen years in SVP positions. During nine years Chairman of the Board in Møller & Devicon A/S, special machine manufacturer to pharma industry.

Claus Demant member of the board

Claus Demant

Co-founder and Member of the Board

General Manager, Glyn Peter Machin A/S. E*MBA from SIMI, HD (A) from Copenhagen Business School. 25 years of experience in

...
Read More
Claus Demant member of the board
Claus Demant

Co-founder and Member of the Board

General Manager, Glyn Peter Machin A/S. E*MBA from SIMI, HD (A) from Copenhagen Business School. 25 years of experience in leadership, strategy, business development, and international experience from IT, Electronics and MedTech industry. Regional Leadership positions in Creative Labs and SVP position in Daymen Acquisition S.A.

Paul Jansen

Member of the board

Former Global Head of Medical Device Development for Sanofi. Professional Engineer with more than twenty-five years of experience in medical

...
Read More
Paul Jansen

Member of the board

Former Global Head of Medical Device Development for Sanofi. Professional Engineer with more than twenty-five years of experience in medical devices. Extensive experience in the design, development, manufacturing and lifecycle management of medical devices, including Lantus SoloStar. Active member of the International Standards Organisation and currently co-chair of TC84.

Contact

Subcuject ApS

Nordre Strandvej 119, F1
DK-3150 Hellebaek
Denmark

Claus Schmidt Møller

Founder and CTO

Phone: +45 2773 6420
csm@subcuject.com